Thursday, May 30, 2013

Mitsubishi Tanabe files Canagliflozin for approval in Japan

Mitsubishi Tanabe Pharma Corporation  has submitted to the Ministry of Health, Labor and Welfare in Japan an application for the manufacturing and marketing approval of TA-7284 (generic name: canagliflozin), a sodium glucose co-transporter 2 (SGLT2) inhibitor, for the treatment of patients with type 2 diabetes.  Canagliflozin discovered by Mitsubishi Tanabe is already approved by the USFDA. JNJ will be marketing canagliflozin in the US.  EU approval is still awaited.


Enter your email address:


Delivered by FeedBurner